Johnson & Johnson ROE 2012-2026 | JNJ
Current and historical return on equity (ROE) values for Johnson & Johnson (JNJ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Johnson & Johnson ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-03-31 | $21.04B | $59.82B | 35.17% |
| 2025-12-31 | $26.80B | $79.35B | 33.78% |
| 2025-09-30 | $25.12B | $76.84B | 32.69% |
| 2025-06-30 | $22.66B | $74.56B | 30.39% |
| 2025-03-31 | $21.81B | $72.82B | 29.95% |
| 2024-12-31 | $14.07B | $70.80B | 19.87% |
| 2024-09-30 | $14.68B | $70.12B | 20.94% |
| 2024-06-30 | $38.02B | $70.39B | 54.01% |
| 2024-03-31 | $38.48B | $71.61B | 53.73% |
| 2023-12-31 | $35.15B | $71.82B | 48.95% |
| 2023-09-30 | $34.62B | $73.83B | 46.90% |
| 2023-06-30 | $13.05B | $74.67B | 17.48% |
| 2023-03-31 | $12.72B | $74.66B | 17.04% |
| 2022-12-31 | $17.94B | $75.62B | 23.73% |
| 2022-09-30 | $19.16B | $74.92B | 25.57% |
| 2022-06-30 | $18.37B | $73.84B | 24.87% |
| 2022-03-31 | $19.83B | $72.15B | 27.49% |
| 2021-12-31 | $20.88B | $69.93B | 29.86% |
| 2021-09-30 | $17.88B | $67.24B | 26.59% |
| 2021-06-30 | $17.77B | $65.79B | 27.01% |
| 2021-03-31 | $15.12B | $64.14B | 23.57% |
| 2020-12-31 | $14.71B | $63.01B | 23.35% |
| 2020-09-30 | $16.99B | $62.05B | 27.37% |
| 2020-06-30 | $15.19B | $60.49B | 25.10% |
| 2020-03-31 | $17.17B | $59.94B | 28.64% |
| 2019-12-31 | $15.12B | $59.36B | 25.47% |
| 2019-09-30 | $14.15B | $59.43B | 23.81% |
| 2019-06-30 | $16.33B | $61.03B | 26.76% |
| 2019-03-31 | $14.68B | $61.56B | 23.85% |
| 2018-12-31 | $15.30B | $62.63B | 24.42% |
| 2018-09-30 | $1.54B | $62.73B | 2.46% |
| 2018-06-30 | $1.37B | $65.07B | 2.11% |
| 2018-03-31 | $1.25B | $67.33B | 1.85% |
| 2017-12-31 | $1.30B | $69.10B | 1.88% |
| 2017-09-30 | $15.83B | $71.67B | 22.08% |
| 2017-06-30 | $16.34B | $71.36B | 22.89% |
| 2017-03-31 | $16.51B | $71.50B | 23.08% |
| 2016-12-31 | $16.54B | $72.08B | 22.95% |
| 2016-09-30 | $15.94B | $72.26B | 22.06% |
| 2016-06-30 | $15.03B | $71.96B | 20.88% |
| 2016-03-31 | $15.55B | $71.62B | 21.71% |
| 2015-12-31 | $15.41B | $70.43B | 21.88% |
| 2015-09-30 | $14.72B | $70.08B | 21.00% |
| 2015-06-30 | $16.11B | $71.34B | 22.58% |
| 2015-03-31 | $15.92B | $73.07B | 21.78% |
| 2014-12-31 | $16.32B | $75.24B | 21.69% |
| 2014-09-30 | $17.32B | $76.32B | 22.70% |
| 2014-06-30 | $15.55B | $74.62B | 20.84% |
| 2014-03-31 | $15.06B | $72.53B | 20.77% |
| 2013-12-31 | $13.83B | $70.09B | 19.73% |
| 2013-09-30 | $12.88B | $67.79B | 19.00% |
| 2013-06-30 | $12.87B | $66.28B | 19.41% |
| 2013-03-31 | $10.44B | $63.97B | 16.32% |
| 2012-12-31 | $10.85B | $62.60B | 17.34% |
| 2012-09-30 | $8.50B | $60.66B | 14.02% |
| 2012-06-30 | $8.74B | $60.10B | 14.54% |
| 2012-03-31 | $10.11B | $60.53B | 16.70% |
| 2011-12-31 | $9.67B | $60.15B | 16.08% |
| 2011-09-30 | $11.40B | $60.03B | 18.99% |
| 2011-06-30 | $11.61B | $58.97B | 19.69% |
| 2011-03-31 | $12.28B | $56.65B | 21.69% |
| 2010-12-31 | $13.33B | $54.91B | 24.28% |
| 2010-09-30 | $13.60B | $53.41B | 25.46% |
| 2010-06-30 | $13.53B | $51.68B | 26.17% |
| 2010-03-31 | $13.29B | $50.03B | 26.55% |
| 2009-12-31 | $12.27B | $47.75B | 25.69% |
| 2009-09-30 | $12.77B | $45.73B | 27.93% |
| 2009-06-30 | $12.74B | $44.57B | 28.58% |
| 2009-03-31 | $12.86B | $44.62B | 28.82% |
| 2008-12-31 | $12.95B | $45.08B | 28.73% |
| 2008-09-30 | $12.61B | $45.28B | 27.85% |
| 2008-06-30 | $11.85B | $44.74B | 26.48% |
| 2008-03-31 | $11.60B | $43.91B | 26.42% |
| 2007-12-31 | $10.58B | $42.74B | 24.75% |
| 2007-09-30 | $10.37B | $41.74B | 24.85% |
| 2007-06-30 | $10.58B | $40.99B | 25.82% |
| 2007-03-31 | $10.32B | $40.39B | 25.55% |
| 2006-12-31 | $11.05B | $40.44B | 27.33% |
| 2006-09-30 | $10.98B | $40.29B | 27.25% |
| 2006-06-30 | $10.76B | $39.36B | 27.34% |
| 2006-03-31 | $10.53B | $37.96B | 27.73% |
| 2005-12-31 | $10.06B | $36.10B | 27.87% |
| 2005-09-30 | $8.85B | $34.37B | 25.76% |
| 2005-06-30 | $8.66B | $33.04B | 26.20% |
| 2005-03-31 | $8.53B | $31.76B | 26.85% |
| 2004-12-31 | $8.18B | $30.47B | 26.85% |
| 2004-09-30 | $9.14B | $29.23B | 31.26% |
| 2004-06-30 | $8.87B | $27.79B | 31.91% |
| 2004-03-31 | $7.62B | $26.39B | 28.88% |
| 2003-12-31 | $7.20B | $25.27B | 28.48% |
| 2003-09-30 | $6.74B | $24.23B | 27.80% |
| 2003-06-30 | $6.39B | $23.31B | 27.40% |
| 2003-03-31 | $6.83B | $22.68B | 30.13% |
| 2002-12-31 | $6.60B | $22.60B | 29.19% |
| 2002-09-30 | $6.32B | $22.98B | 27.49% |
| 2002-06-30 | $6.12B | $23.40B | 26.17% |
| 2002-03-31 | $5.95B | $23.60B | 25.21% |
| 2001-12-31 | $5.67B | $22.69B | 24.98% |
| 2001-09-30 | $5.45B | $21.73B | 25.10% |
| 2001-06-30 | $5.25B | $20.42B | 25.70% |
| 2001-03-31 | $5.13B | $19.24B | 26.66% |
| 2000-12-31 | $4.89B | $18.50B | 26.43% |
| 2000-09-30 | $4.75B | $17.46B | 27.23% |
| 2000-06-30 | $4.54B | $16.68B | 27.23% |
| 2000-03-31 | $4.34B | $15.87B | 27.36% |
| 1999-12-31 | $4.17B | $15.14B | 27.52% |
| 1999-09-30 | $3.52B | $14.49B | 24.27% |
| 1999-06-30 | $3.37B | $14.12B | 23.85% |
| 1999-03-31 | $3.22B | $13.77B | 23.41% |
| 1998-12-31 | $3.00B | $13.41B | 22.39% |
| 1998-09-30 | $3.53B | $13.10B | 26.95% |
| 1998-06-30 | $3.42B | $12.67B | 27.02% |
| 1998-03-31 | $3.31B | $12.27B | 27.01% |
| 1997-12-31 | $3.30B | $11.86B | 27.85% |
| 1997-09-30 | $3.23B | $11.48B | 28.13% |
| 1997-06-30 | $3.12B | $11.10B | 28.14% |
| 1997-03-31 | $3.01B | $10.73B | 28.01% |
| 1996-12-31 | $2.89B | $10.40B | 27.77% |
| 1996-09-30 | $2.80B | $9.95B | 28.11% |
| 1996-06-30 | $2.67B | $9.51B | 28.08% |
| 1996-03-31 | $2.54B | $9.09B | 27.94% |
| 1995-12-31 | $2.40B | $8.60B | 27.94% |
| 1995-09-30 | $2.32B | $8.12B | 28.52% |
| 1995-06-30 | $2.22B | $7.64B | 29.03% |
| 1995-03-31 | $2.12B | $7.15B | 29.58% |
| 1994-12-31 | $2.01B | $6.71B | 29.91% |
| 1994-09-30 | $1.96B | $6.32B | 31.07% |
| 1994-06-30 | $1.89B | $5.99B | 31.56% |
| 1994-03-31 | $1.83B | $5.77B | 31.71% |
| 1993-12-31 | $1.79B | $5.63B | 31.75% |
| 1993-09-30 | $1.76B | $5.53B | 31.82% |
| 1993-06-30 | $1.72B | $5.60B | 30.71% |
| 1993-03-31 | $1.68B | $5.60B | 29.93% |
| 1992-12-31 | $1.65B | $5.65B | 29.19% |
| 1992-09-30 | $1.62B | $5.76B | 28.05% |
| 1992-06-30 | $1.57B | $5.61B | 27.91% |
| 1992-03-31 | $1.52B | $5.45B | 27.89% |
| 1991-12-31 | $1.46B | $5.24B | 27.86% |
| 1991-09-30 | $1.42B | $5.06B | 28.03% |
| 1991-06-30 | $1.37B | $4.91B | 27.91% |
| 1991-03-31 | $1.32B | $4.78B | 27.56% |
| 1990-12-31 | $1.14B | $4.62B | 24.75% |
| 1990-09-30 | $1.11B | $4.43B | 25.14% |
| 1990-06-30 | $1.07B | $4.23B | 25.19% |
| 1990-03-31 | $1.01B | $4.03B | 25.04% |
| 1989-12-31 | $1.08B | $3.86B | 28.01% |
| 1989-09-30 | $1.06B | $3.70B | 28.72% |
| 1989-06-30 | $1.04B | $3.60B | 28.87% |
| 1989-03-31 | $1.01B | $3.56B | 28.45% |
| 1988-12-31 | $0.97B | $3.57B | 27.28% |
| 1988-09-30 | $0.95B | $3.57B | 26.73% |
| 1988-06-30 | $0.92B | $3.51B | 26.29% |
| 1988-03-31 | $0.88B | $3.40B | 25.76% |
| 1987-12-31 | $0.83B | $3.24B | 25.72% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |